Falling Pregnant on Mounjaro: What the Guidance Actually Says

What does the guidance say about getting pregnant while taking Mounjaro?

The short answer: Mounjaro should be stopped before trying to conceive. The tirzepatide SmPC and NHS prescribing guidance both advise that the medicine is not suitable in pregnancy, and that women who want to become pregnant should discontinue treatment in advance and allow a wash-out period. The MHRA and NHS England's clinical guidance on weight-management injections is explicit on this point. A wash-out period matters because tirzepatide remains in the body for some weeks after the last dose; the SmPC gives specific detail on this, so it is worth discussing the exact timeframe with your GP or prescriber rather than relying on a general figure.

Animal reproductive studies with tirzepatide did show adverse developmental outcomes at doses that produced high drug exposure. That does not automatically translate to equivalent risk in humans at therapeutic doses, but it is the basis for the precautionary recommendation. Human data from accidental pregnancy exposure is limited. The honest clinical position is that the risk cannot be quantified accurately, which is precisely why stopping before conception is the advised course. If you have questions about timing or what the wash-out means practically, your GP or the clinical team who manages your prescription are the right people to ask.

What should you do if you discover you are already pregnant?

Stop Mounjaro and contact your GP or midwifery team as soon as possible. This is not a situation where you wait until your next scheduled clinical review or run out your current pen. The relevant page on Mounjaro use when pregnant covers the practical steps in more detail, but the headline is simple: same day, call your GP.

Your maternity team will want to know the dose you were taking and roughly how far into your cycle the exposure occurred, and our guidance on Mounjaro and pregnancy explains what information to have ready when you make that call. The MHRA's Yellow Card scheme at yellowcard.mhra.gov.uk also allows healthcare professionals and patients to report suspected medicine effects in pregnancy, which contributes to the evidence base for future guidance. Reporting is voluntary, but it is genuinely useful.

One thing worth knowing: the weight that returns after stopping a GLP-1 medicine can be significant, and some women find that affects them emotionally as well as physically during pregnancy. That is a conversation worth having early with your maternity team, who can connect you with the right support.

Can Mounjaro affect fertility or the chances of conceiving in the first place?

This is a question that sits at the intersection of a few different clinical threads. Weight loss itself, achieved through any route, is associated with improved hormonal regulation in some people, particularly those with conditions like polycystic ovary syndrome (PCOS) where excess weight can affect ovulation. If you are wondering whether you can fall pregnant on Mounjaro, that improved hormonal regulation is part of the picture, because some women may find their fertility improves while losing weight, even if they were not expecting it.

There is also the contraception point, which is worth spelling out plainly. Mounjaro slows gastric emptying, which can temporarily reduce how much of an oral contraceptive tablet the body absorbs. NHS guidance recommends adding a non-oral contraceptive method for the first four weeks of starting Mounjaro and for four weeks after each dose increase. Condoms are a practical choice. Women using patches, implants, injections or the coil are not affected in the same way. If you are on the combined or progesterone-only pill and started Mounjaro recently, it is worth discussing your contraceptive cover with your GP or our clinical team before assuming you are fully protected.

The broader question of whether tirzepatide directly affects fertility in humans is not yet well studied. For those who have already conceived while on treatment, our page on getting pregnant on Mounjaro covers what that situation typically involves and what steps to take. What the data does not show is a clear direct adverse effect on ovulation in women at licensed doses, but that absence of evidence is not the same as reassurance, and the current guidance does not treat it as such.

What happens to treatment after a pregnancy or if plans change?

Mounjaro is also not recommended during breastfeeding, because it is not known whether tirzepatide passes into human breast milk or what effect that might have on a newborn. The guidance is to avoid it until breastfeeding has stopped. After that point, restarting treatment is a decision made with a prescriber, who will reassess your clinical picture from the beginning, including your BMI, any new health conditions, and what you want from treatment.

If your situation has changed and you are now exploring weight-loss treatment options more broadly, our weight-loss treatments overview covers what is licensed in the UK. And if you want to understand more about Mounjaro as a treatment before any future consultation, the Mounjaro information page sets out how it works, who it is licensed for, and what the clinical evidence shows. For those thinking about cost alongside clinical factors, Mounjaro pricing in the UK gives honest context on what private treatment involves. Starting a fresh consultation when the time is right is straightforward: a prescriber reviews your situation individually, with no algorithm making decisions on their behalf.